Verdiva Bio Dev Limited
Clinical-stage biopharmaceutical company developing next-generation oral and injectable peptide therapies for obesity and cardiometabolic disorders. The company focuses on oral peptide delivery and co-formulation approaches to enable less-frequent dosing (once-weekly), with a portfolio that includes GLP-1 and amylin receptor agonist programs and combination therapy development. Verdiva launched with Series A financing to advance clinical development and expand its portfolio.
Industries
Nr. of Employees
small (1-50)
Verdiva Bio Dev Limited
25 Austen Road, Guildford, England, GU1 3NP
Products
Oral GLP-1 receptor agonist candidate (once-weekly formulation)
An investigational oral GLP-1 peptide developed to achieve systemic exposure enabling once-weekly dosing for weight reduction and maintenance.
Oral amylin analog candidate (once-weekly formulation)
An investigational oral amylin analog designed for once-weekly dosing, under development as monotherapy and in co-formulation with oral GLP-1 analogs.
Long-acting subcutaneous amylin agonist candidate
A long-acting injectable amylin agonist under development for weekly subcutaneous administration, intended for use alone or in combination with oral GLP-1 peptides.
Oral GLP-1 receptor agonist candidate (once-weekly formulation)
An investigational oral GLP-1 peptide developed to achieve systemic exposure enabling once-weekly dosing for weight reduction and maintenance.
Oral amylin analog candidate (once-weekly formulation)
An investigational oral amylin analog designed for once-weekly dosing, under development as monotherapy and in co-formulation with oral GLP-1 analogs.
Long-acting subcutaneous amylin agonist candidate
A long-acting injectable amylin agonist under development for weekly subcutaneous administration, intended for use alone or in combination with oral GLP-1 peptides.
Expertise Areas
- Oral peptide therapeutics
- Clinical trial management (early-phase)
- Pharmacokinetics and bioavailability assessment
- Preclinical obesity and metabolic disease models
Key Technologies
- Proprietary oral peptide delivery platform
- Peptide co-formulation in single-tablet oral dosage
- Once-weekly peptide dosing formulations
- cAMP-biased GLP-1 analog design
News & Updates
Named by industry publication as one of 2025's Fierce 15 biotechnology companies.
Presented Phase 1 clinical pharmacokinetic data and preclinical data on oral GLP-1 and amylin candidates demonstrating once-weekly potential.
Company launch as a clinical-stage cardiometabolic company with Series A financing to advance next-generation oral and injectable therapies.
Scheduled presentations highlighting once-weekly potential of oral GLP-1 and oral amylin candidates and co-formulation data.
Selected by Fierce Biotech as one of its 2025 Fierce 15 biotechnology companies.
Named by industry publication as one of 2025's Fierce 15 biotechnology companies.
Presented Phase 1 clinical pharmacokinetic data and preclinical data on oral GLP-1 and amylin candidates demonstrating once-weekly potential.
Company launch as a clinical-stage cardiometabolic company with Series A financing to advance next-generation oral and injectable therapies.
Scheduled presentations highlighting once-weekly potential of oral GLP-1 and oral amylin candidates and co-formulation data.
Selected by Fierce Biotech as one of its 2025 Fierce 15 biotechnology companies.